

11 Dec 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's edition of Five Must-Know Things: another acquisition for AbbVie; Roche buys into the obesity market; J&J's oral immunology push; oral incretins advance; and AstraZeneca on Chinese innovation.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 December 2023, including: another acquisition for [AbbVie Inc.](#); [Roche Holding AG](#) buys into the obesity market; [Johnson & Johnson's](#) oral immunology push; oral incretins advance; and [AstraZeneca PLC](#) on Chinese innovation.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[AbbVie Strikes Again By Teeing Up \\$8.7bn Offer For Cerevel](#)" - Scrip, 6 Dec, 2023.)

(Also see "[Roche Looks To Muscle Into Obesity Market With \\$2.7bn Carmot Buyout](#)" - Scrip, 4 Dec, 2023.)

(Also see "[J&J In Immunology: 'We Plan To Lead The Orals Market'](#)" - Scrip, 6 Dec, 2023.)

(Also see "[Time For Oral Incretins To Prove Their Worth](#)" - Scrip, 5 Dec, 2023.)

(Also see "[AstraZeneca Likes What Chinese Innovation Has To Offer](#)" - Scrip, 6 Dec, 2023.)

[Click here to explore this interactive content online](#) ✨

